Heart attack drug shows promise for Non-Diabetics

NCT ID NCT06903754

Completed Disease control Sponsor: Mohammed VI University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study tested whether SGLT2 inhibitors (dapagliflozin or empagliflozin), taken daily, can reduce heart failure hospitalizations, repeat heart attacks, and death in 450 non-diabetic patients who had a heart attack treated with stenting. Participants received the drug on top of standard care. The goal is to see if these medications, already used in diabetes, can also protect the heart in people without diabetes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SGLT2 inhibitors (dapagliflozin or empagliflozin)
What this could lead to: If successful, this could show that SGLT2 inhibitors help prevent heart failure and reduce hospital readmissions in non-diabetic patients after a heart attack.
What could go wrong: The trial is completed but results are not yet widely confirmed. Benefits seen in diabetic patients may not fully apply to non-diabetics, and side effects like dehydration or kidney issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome heart failure myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE CORONARY SYNDROMES HEART FAILURE

Contacts and locations

Locations

Mohammed VI university hospital oujda

OUDA, Morocco

More trials for these conditions

Other studies related to the condition(s) this trial covers.